Literature DB >> 32548660

Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia.

Paul R J Ames1,2, Susan Jeffrey3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32548660     DOI： 10.1007/s00277-020-04135-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

Review 1.  Development of New Drugs for Autoimmune Hemolytic Anemia.

Authors:  Zhengrui Xiao; Irina Murakhovskaya
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

2.  Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia.

Authors:  Mingkang Yao; Jingjing Zhang; Ying Li; Linlin Lv; Lu Jia; Chunyan Yang; Yu Huang; Haihui Liu; Jian Wang; Mingtai Chen; Hao Zhang
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.